INS and Hypoglycemia: This comparable reduction in HbA1c (LS mean treatment difference 0.01% ‘with DPPIVi’ and −0.03% ‘without DPPIVi’), accompanied by the lower risk of hypoglycaemia with Gla-300 versus Gla-100, was associated with a numerically higher daily insulin dose for Gla-300, regardless of DPPIVi use (note statistical testing was not performed on insulin dose).